Our CEO, Artem Andrianov, PhD, will be speaking at this event. Catch up with Artem in Dusseldorf!
It took a pandemic to eventually shift the focus to long-overdue regulatory changes. In this article, we explore the concept of risk-based eCOA and how it has evolved over time to befit this ‘new normal’ phase.
Dr Johann Proeve, CSO Cyntegrity, will update you on the recently published FDA and EMA "guidance on the management of clinical trials during the COVID-19 pandemic"; a clear overview of what's new and different, and how it affects your current and future studies.
MyRBQM® Portal's new Machine Learning predictive analytics model is far less sensitive to noise, it better generalizes data, and provides narrower CIs in long time series. Singular Spectrum Analysis is particularly valuable for long time series, as mostly observed in clinical trials.
Artem Andrianov, PhD, our CEO, will be one of the key-note speakers at the New Dawn virtual summit organized by KP Morgan. Artem will be speaking about the post-COVID transformation in BioPharma. Our guests can attend at 50% discounted pass.
We've created this "ask the experts" Q&A to provide clear responses to the questions that were most often asked by the forum's participants.
During this virtual discussion forum BioPharma industry experts are putting their minds together to combat the impact of the Coronavirus outbreak on clinical trials, and be better prepared in the future.
Join this free webinar: In Part II of "Dealing with Resistance - Facilitate Successful RBQM" Linda Bunschoten, CMO Cyntegrity, will address the Agile Change Management concept.
Frontiers Health Ecosystem Companies Fighting Back the COVID-19 Outbreak As the COVID-19 outbreak continues, it has become even more challenging for patients to seek in- person medical care and for healthcare providers (HCP) to guarantee community health services for people who may have symptoms [...]
Cyntegrity developed a special COVID-19 RACT that guides those involved in clinical trials on specific risks which may arise as a result of COVID-19, and how they can mitigate them. This special RACT is part of the COVID-19 rapid deployment pack for ad-hoc centralized monitoring.